Success Story: Decoding Protein Structures and Disease Mechanisms Through EB1B Approval for a Chemistry Researcher
Client’s Testimonial:
"I am very satisfied with the service.”
On February 14th, 2026, we received another EB-1B (Outstanding Professors and Researchers) approval for a Senior Research Scientist in the Field of Structural Biology (Approval Notice).
General Field: Structural Biology
Position at the Time of Case Filing: Senior Research Scientist
Country of Origin: India
State of Residence at the Time of Filing: New York
Approval Notice Date: February 14th, 2026
Processing Time: 13 months, 18 days
Case Summary:
With a Ph.D. in chemistry, the client earned approval of the I-140 EB1B petition based on a strong record in structural biology. The client’s research has focused on protein structures and the molecular mechanisms underlying important biological processes, including bacterial pathogenicity, immune response modulation, ion channel function, and advances in NMR spectroscopy. The petition emphasized that this work has practical scientific value because it supports drug design against infections, helps improve therapies for autoimmune conditions, and strengthens molecular-level understanding relevant to disease research.
To demonstrate that the client qualifies as an outstanding researcher, we highlighted a focused record of achievement rather than relying on metrics alone. At the time of filing, the client had authored 7 peer-reviewed journal articles, including 1 first-authored and 1 co-first-authored article, as well as 1 first-authored abstract. The client’s work had also been cited 240 times, which helped show independent reliance by other researchers and supported the argument that the contributions had already influenced the field. In addition, the client had completed at least 27 reviews, reflecting professional trust in the client’s scientific judgment.
The petition also documented major funding support connected to the client’s work, including support from the National Institutes of Health (NIH), the Starr Cancer Consortium, and the Leon Levy Foundation. Along with 2 recommendation letters from experts in the field, this evidence helped show that the client’s research was original, significant, and internationally recognized. One expert stated:
“Further, his impressive research contributions and peer review have positioned [Client] as a leader in the international structural biology field. It benefits American public health and safety for his research to continue.”
We congratulate our client on this I-140 EB1B approval and look forward to the continued impact of the client’s research.